1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

Summary

Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort or pain, bloating, and changes in bowel habit. Due to the lack of a demonstrable structural abnormality to explain these symptoms, IBS is classified as a functional gastrointestinal disorder.

IBS is one of the most common gastrointestinal disorders; moreover, it has a significant negative impact on a patient’s quality of life and social functioning. That said, IBS is not known to be associated with the development of serious disease or with excess mortality. Several factors, including psychological disorders, stress, environmental factors, infection, and inflammation have been reported to play a role in the pathogenesis of IBS, however, their exact role remains to be clarified.

GlobalData epidemiologists forecast that the total prevalent cases of IBS in the 7MM will increase from 40,777,607 total prevalent cases in 2013 to 42,366,389 by 2023, at a decadal growth rate of 3.9%. Specifically, Spain will have the highest growth in the total prevalent cases of IBS in the 7MM between 2013 and 2023, while Japan and Germany will have a decline in the total prevalent cases of IBS in the 7MM between 2013 and 2023.

GlobalData’s epidemiological analysis is supported by the use of epidemiological studies published in peer-reviewed journals and country-specific studies that provided the total prevalence of IBS using the Rome II diagnostic criteria. GlobalData epidemiologists used uniform methodology across the markets to forecast the total prevalent cases of IBS; GlobalData epidemiologists segmented IBS by sex, age, and subclassification of predominant bowel habits, which allows for a meaningful comparison of the disease populations between markets.

Scope

- The Irritable Bowel Syndrome (IBS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IBS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of IBS segmented by sex, age (10-18 years, 19-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, and =85 years), and subclassification of predominant bowel habits (diarrhea-predominant IBS [IBS-D], constipation-predominant IBS [IBS-C], mixed presentation IBS [IBS-M], and unsubtyped IBS [IBS-U] in these markets.
- The IBS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global IBS market.
- Quantify patient populations in the global IBS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IBS therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023
1 Table of Contents
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 10
3.3.1 US 13
3.3.2 5EU 14
3.3.3 Japan 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 16
3.4.2 Sources Not Used 22
3.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of IBS 23
3.4.4 Forecast Assumptions and Methods - IBS Subtype Segmentations 26
3.5 Epidemiological Forecast for IBS (2013-2023) 28
3.5.1 Total Prevalent Cases of IBS 28
3.5.2 Age-Specific Total Prevalent Cases of IBS 30
3.5.3 Sex-Specific Total Prevalent Cases of IBS 32
3.5.4 Age-Standardized Total Prevalence of IBS 34
3.5.5 Total Prevalent Cases of IBS by Clinical Subtype 35
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
3.6.2 Limitations of the Analysis 38
3.6.3 Strengths of the Analysis 39
4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 45
4.2.1 Epidemiologists 45
4.2.2 Reviewers 45
4.2.3 Acting Global Director of Epidemiology 46
4.2.4 Global Head of Healthcare 47
4.3 About GlobalData 48
4.4 About EpiCast 48
4.5 Disclaimer 48

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for IBS 9
Table 2: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies 12
Table 3: Total Prevalence (%) of IBS in the 7MM, as Reported in Epidemiological Studies 12
Table 4: Total Prevalence (%) of IBS in the US, as Reported in Epidemiological Studies 14
Table 5: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of IBS 16
Table 6: 7MM, Sources of IBS Subtype Data Used to Forecast the Total Prevalent Cases of IBS by Subtype 17
Table 7: 7MM, Total Prevalent Cases of IBS, Ages ?10 Years, Both Sexes, N, Selected Years 2013-2023 29
Table 8: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N (Row %), 2013 31
Table 9: 7MM, Sex-Specific Prevalent Cases of IBS, Ages ?10 Years, N (Row %), 2013 33
Table 10: 7MM Total Prevalent Cases of IBS, N (%), by Clinical Subtype, Both Sexes, Ages ?10 Years, 2013 36

1.2 List of Figures

Figure 1: 7MM, Total Prevalent Cases of IBS Ages ?10 Years, Both Sexes, N, 2013-2023 30
Figure 2: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N, 2013 32
Figure 3: 7MM, Sex-Specific Total Prevalent Cases of IBS, Ages ?10 Years, N, 2013 34
Figure 4: 7MM, Age-Standardized Total Prevalence of IBS (%), Ages ?10 Years, by Sex, 2013 35
Figure 5: 7MM Total Prevalent Cases of IBS (%), by Clinical Subtype, Both Sexes, Ages ?10 Years, 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

This BCC Research report presents a comprehensive look at disorders of the gastrointestinal system and their pharmacological treatment and diagnostic options. Forecast included from 2016 through 2021. ...

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Gastroesophageal Reflux Disease (GERD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Gastroesophageal ...

Global Proton Pump Inhibitors Market - Growth, Trends, and Forecasts (2016 - 2021)

Global Proton Pump Inhibitors Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global proton pump inhibitors market accounted for USD XX million in 2015 and is expected to reach USD XX million in 2016. The market is expected to reach USD XX million by 2021, growing at a CAGR ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.